The optimal management of men with very favorable clinicopathological factors who develop biochemical recurrence (BCR) after radical prostatectomy (RP) has not been previously reported. Both local and systemic recurrences are unlikely in this cohort. This study examines their management and outcomes. Between October 2000 to March 2010, 1627 men underwent open RP by a single surgeon. In all, 448 (27.5%) met the following criteria for extremely low risk disease: preoperative PSA level o10 ng ml
Introduction
Several clinical and pathological features predict disease recurrence following radical prostatectomy (RP). Serum PSA, Gleason score and clinical stage have consistently been shown to independently predict biochemical recurrence (BCR) after RP.
1-3 D'Amico et al. 4 combined these three parameters to preoperatively stratify men into three groups according to the risk of BCR after RP. The addition of pathological findings from the prostatectomy specimen, including positive surgical margins and extracapsular extension, has been used to construct postoperative nomograms predicting BCR. 5 The management of men with an extremely low risk of BCR who actually develop recurrent disease presents a management dilemma, as neither local nor metastatic recurrence is expected in this cohort. In many of these cases, salvage radiation therapy would be offered if there was a realistic expectation that the intervention would effectively eradicate the disease. The objective of this study is to provide insights how to manage recurrent disease in a very low risk group.
On the basis of a widely used nomogram, an individual with a preoperative PSA o10 ng ml
À1
, clinical stage T1c/T2a, Gleason score in the surgical specimen o7, pathological pT2 disease and negative surgical margins has a risk of BCR at 5 years following RP of B2%. 5 Tumor volume in the surgical specimen has been shown to be an independent predictor of BCR. 6 Therefore, we added tumor volume o5% of the surgical specimen to the above criteria to identify a cohort with extremely low risk for BCR following RP. This is the first report to critically examine the management and outcomes of men who were at an extremely low risk of BCR following RP who subsequently developed disease recurrence.
Materials and methods
Between October 2000 to March 2010, 1627 men underwent open radical retropubic prostatectomy by a single surgeon using a previously described surgical technique, 7 and signed informed consent to participate in an institutional review board approved prospective and longitudinal outcomes study before undergoing open RP. The surgical specimens were examined by a group of board-certified pathologists using a standardized processing and reporting protocol. 8 Tumor volume was estimated to occupy o5%, 5-24% or X25% of the prostatectomy specimen.
The database was retrospectively queried for clinical and pathological factors which met our criteria for extremely low risk disease, which included the following: preoperative PSA level o10 ng ml À1 , clinical stage T1c or T2a, Gleason score p6, an estimated cancer volume in the prostatectomy specimen of o5% and no evidence of positive surgical margins. Of the 1627 men in the outcomes study, 448 (27.5%) fulfilled our criteria for having an extremely low risk of developing BCR.
Serum PSA levels were routinely measured at 3, 6, 12, 18, 24, 30 and 36 months postoperatively and annually thereafter. Of the 448 men, 441 (98%) had PSA drawn beyond 3 months of follow-up. If clinically indicated, additional PSA measurements were obtained. The American Urological Association Symptom Score and the University of California, Los Angeles, Prostate Cancer Index were administered at baseline and at specified time points throughout the study. In addition, at every follow-up visit, subjects were queried if they underwent any adjuvant or salvage intervention such as salvage radiation therapy (SRT).
A full-time data manager was responsible for maximizing response rates at all time points. Subjects not responding to annual mailings were contacted via telephone and urged to complete the annual survey.
Biochemical recurrence was defined as a PSA X0.2, or initiation of salvage radiation therapy for a progressively rising PSA. PSA doubling time (PSADT) was calculated according to the 'natural log of 2 divided by the slope of the relationship between the log of PSA and time of PSA measurement'. 9 Statistical analysis was carried out using Microsoft Excel 2010.
Results
A total of 448 men met our definition of extremely low risk disease as defined by clinical and pathological criteria. The preoperative and postoperative characteristics of this group are summarized in Table 1 .
Mean age was 57.5 ± 6.7 years, and mean preoperative serum PSA was 4.6±2 ng ml
À1
. The proportion of clinical stage T1c and T2a was 93 and 7%, respectively. Mean follow-up was 54.4±27.7 months (range 3-114).
Overall, nine (2%) of men who fulfilled our criteria for extremely low risk of developing disease recurrence actually developed BCR. Table 2 shows the characteristics of these nine men. In eight of these men, the PSA reached a level X0.2 ng ml À1 , whereas only one underwent SRT for a progressively rising PSA level to 0.15 ng ml
. The mean PSADT was 15 ± 9 months (range 6-27). Of the nine men developing a BCR, six underwent SRT, two pursued surveillance and one was lost to follow-up. The two men managed with surveillance were encouraged to pursue this option because the recurrence was felt not to be clinically significant. In subject 7, although the PSADT of 9 months was judged to be consistent with a cancer recurrence, a conservative approach was encouraged because the BCR developed at the age of 75 years. In subject 8, the BCR occurred almost 8 years after open RP, and the PSADT of 2 years was felt to be most consistent with residual benign prostatic tissue. SRT will be considered in this case if there is an acceleration of the PSADT.
Of the subjects undergoing SRT, the mean age was 62 years, the mean time to recurrence was 60 months and the mean PSADT was 14 months. All these parameters suggested the recurrence was likely attributable to a biologically significant cancer recurrence in cases selected for SRT. All men underwent a bone scan, abdominal/pelvic imaging with a computerized tomography or magnetic resonance imaging and prostascint scan before initiating SRT. None of these imaging studies were suspicious for local, regional or systemic disease recurrence. None of the men received neoadjuvant or adjuvant androgen deprivation therapy as part of their radiation therapy protocol. The SRT was carried out at many different facilities. It is unknown whether the lymph nodes were included in the radiation field.
All men who underwent SRT were observed to have at least a 75% reduction in the pre-SRT PSA level and in all cases the PSA declined to levels o0.1 ng ml
. With a mean follow-up of 26 months after SRT, all PSA levels remain o0.1 ng ml
. These PSA responses indicate that in all cases the etiology for the BCR was amenable to SRT.
Discussion
D'Amico et al. 4 combined serum PSA, biopsy Gleason score and clinical stage to define low, intermediate and high risk groups for BCR following RP. The low risk group was defined by a PSA o10, Gleason score p6 and clinical stage T2a or less. Biochemical recurrence has been reported to occur in 12% of these men at 8 years after RP. 10 Using the Kattan nomogram, an individual with these low risk pre-operative characteristics and no evidence of extracapsular extension or positive surgical margins after RP has a 3% probability of BCR at 10 years. 5 Furthermore, percentage of tumor volume in biopsy specimens enhanced the ability to preoperatively predict Percentage or volume of tumor in the surgical specimen has been shown to be an independent predictor of BCR following RP. 12, 13 Therefore, in this study, we added estimated tumor volume in the surgical specimen o5% to the established low risk characteristics of preoperative PSA level o10 ng ml In men with low risk of developing BCR following RP who develop disease recurrence, it is unclear whether the source of recurrence is amenable to SRT. As the risk of recurrence is so low, there is no basis for speculating whether the recurrence is attributable to local, regional or systemic disease. The site of disease would influence management of the disease recurrence. We have previously shown that at the time men develop a BCR following open RP, all imaging studies including bone scan, prostacint scan and pelvic/abdominal computerized tomography scans are never positive if the PSADT 43 months.
14 In our cohort of men with low risk of recurrence who developed BCR, the lowest PSADT was 6 months. It is therefore of no surprise that imaging studies failed to localize the recurrent disease in this study.
There is a paucity of information in the literature regarding outcomes following intervention for disease recurrence in men at low risk for BCR. Hernandez et al. 15 studied a cohort of 2526 patients with pT2, Gleason 6 disease and negative surgical margins after RP. Tumor volume information was not included in the selection of the low risk cohort and men with a preoperative PSA 410 were included. On the basis of initial review of the surgical specimens, 36 (1.4%) of the low risk cohort developed a BCR. The surgical specimens were rereviewed by a single pathologist, and 25 of the 36 recurrent cases were upgraded and excluded from the low risk cohort. We did not have a single pathologist retrospectively re-analyze our low risk group.
We feel our low risk cohort is more generalizable to the urological community. Of the remaining 11 (0.5%) low risk men who recurred at 5 years follow-up, 4 underwent SRT, and all developed undetectable PSA levels. The criteria for recommending SRT was not described nor was the fate of the seven men who did not undergo SRT.
At a mean follow-up of 5 years and with up to 10 years follow-up, men in our cohort with low risk prostate cancer had an observed BCR rate of 2%. Our rate of 2% is consistent with the Kattan nomogram and the Hernandez et al. study based on the initial pathological review.
Unlike the series reported by Hernandez et al., all men in our low risk group who were felt to harbor a biologically significant disease recurrence underwent SRT. Of the two men who did not undergo SRT, one was of advanced age, and the other has a PSADT of 2 years, suggestive of a benign etiology. 16 All six men who underwent SRT had at least a 75% decrease in the PSA level, with nadir PSA following SRT consistently o0.1 ng ml À1 , and have experienced a durable PSA response. Although the mean follow-up after SRT was only 2 years, the overall mean follow-up from the time of RP was 86 months. If systemic disease was present, it likely existed at the time of RP and would have been refractory to the SRT resulting in failure to achieve a low nadir level. These observations provide compelling evidence that BCR developing in a cohort of men with a very low risk of developing disease recurrence should be expected to have a favorable response to salvage RT. The decision to offer SRT in this cohort of men should be based on the presumed risk of the disease.
One of the limitations of the study is that it is unknown whether the lymph nodes were included in the radiation field. Salvage RT was performed at six different institutions and the field is not known for certainty. We believe it is not standard of care to include the lymph nodes in a low risk cohort and that the disease recurrence was most likely limited to the prostatic bed.
Another criticism is that only nine recurrences were observed and only six underwent salvage RT. Our series is based on one of the largest single surgeon prospective databases reported in the literature and the small numbers are inherent to the question we ask. Most surgeons will rarely have to deal with this clinical dilemma and will not be able to draw upon their personal experiences for guidance. Approximately 150 000 RPs are performed annually in the United States. 17 Although our findings are relevant to only 2% of men undergoing RP, this translates to B3000 cases a year where the observations of our study may guide management.
Conclusions
In this study, we identified a subset of men with very low risk of developing disease recurrence following open RP. Low risk prostate cancer following radical prostatectomy EW Lee et al
All men with biologically significant disease in this group were offered SRT and experienced a successful outcome. Our findings suggest that men with very low risk for BCR following RP who develop a biologically significant disease recurrence harbor local disease and therefore are excellent candidates for SRT.
